We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Gasper J. LaRosa

Jones Day


Results 1 to 5 of 15
Most popular |Most recent

Lead Compound Analysis Not Applicable to Certain Method-of-Treatment Claims

USA - June 5 2019 The Situation: In a Hatch-Waxman litigation, a district court determined that the claims covering a method of using the drug everolimus to...

Jihong Lou Ph.D..

Precedential: PTAB Considers 314(a) Factors Even When Denying Under 325(d)

USA - May 13 2019 When exercising its broad discretion on whether to institute review, the PTAB is not limited to consideration of factors associated with the type of...

PTAB Grants Rare Motion for Additional Discovery

USA - August 22 2018 The PTAB recently granted a rare motion for additional discovery into the question of whether an unnamed party, Amneal Pharmaceuticals, LLC (“Amneal”)...

Delaware District Dismisses BPCIA "Private Right" Claim; Says Controversy not Sufficiently Immediate

USA - May 10 2018 In a recent decision involving the Biologics Price Competition and Innovation Act ("BPCIA") (Genentech, Inc. and City of Hope v. Amgen Inc.) the...

Shehla Wynne Ph.D., Mital B. Patel.

Federal Circuit Rules BPCIA Preempts State Law

USA - December 22 2017 On December 14, 2017, the U.S. Court of Appeals for the Federal Circuit again interpreted the Biologics Price Competition and Innovation Act...

Timothy J. Heverin, Michael J. Wynne, Adam M. Nicolais.